Puma Biotechnology - Crunchbase Company Profile & Funding
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PBYI - Puma Biotechnology Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology, Inc. (PBYI) Price, Charts, Market Cap, Markets, Exchanges, PBYI to USD Calculator
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
PumaBiotech (@pumabiotech) / X
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology Inc - AnnualReports.com
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K) -December 16, 2022 at 04:18 pm EST | MarketScreener
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology
Articles about Puma Biotechnology
Puma Biotechnology
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology, Inc.
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology (PBYI) Price Target Increased by 5.26% to 5.10
Puma Biotechnology Inc - AnnualReports.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
